Eric Topol June 10, 2022

Ground Truths

A cluster of “un-heard of” results in multiple subtypes of advanced cancer

The narrative has been incubating for many years, but in recent days we are witnessing some extraordinary progress in treating and monitoring cancer. The convergence of genomics of the cancer—be it from the person’s DNA or tumor directly or the blood (known as liquid biopsy)—matched with the appropriate therapy is leading to outcomes that are being described as “unheard-of” by expert oncologists. This represents the essence of individualized medicine, whereby understanding the unique biologic basis of a person’s cancer can lead to highly accurate and effective treatment, and also avoid the toxicity of classical chemotherapeutic agents. Here I will review 4 recent studies, all published in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Patient-derived organoids: Transforming cancer research and personalized medicine

Share This Article